Studies in animal models of NASH have shown that GLP-1 therapy improves insulin sensitivity and reduces hepatic glucose production, and can reduce hepatic steatosis, inflammation, steatohepatitis, and fibrosis (12, 25, 33). This evidence concerns the gene INS and Hepatic steatosis.